Preclinical and clinical development of a dengue recombinant subunit vaccine

• Published in: Vaccine Vol. 33; no. 50; pp. 7126 - 7134
• Main Authors: Manoff, Susan B., George, Sarah L., Bett, Andrew J., Yelmene, Michele L., Dhanasekaran, Govindarajan, Eggemeyer, Linda, Sausser, Michele L., Dubey, Sheri A., Casimiro, Danilo R., Clements, David E., Martyak, Timothy, Pai, Vidya, Parks, D. Elliot, Coller, Beth-Ann G.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 10.12.2015; Elsevier Limited
• Subjects: adjuvants; Adjuvants, Immunologic - administration & dosage; adults; Allergy and Immunology; Aluminum; Aluminum Hydroxide - administration & dosage; Animals; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Antigens; Cholesterol - administration & dosage; Clinical trials; Clinical Trials, Phase I as Topic; dengue; Dengue - epidemiology; Dengue - prevention & control; Dengue fever; Dengue vaccine; Dengue Vaccines - administration & dosage; Dengue Vaccines - genetics; Dengue Vaccines - immunology; Dengue Vaccines - isolation & purification; Dengue virus; Deoxyribonucleic acid; Disease; DNA; Drosophila; Drug Combinations; Drug Evaluation, Preclinical; durability; Flaviviridae; glycoproteins; Hawaii; Humans; Immunization Schedule; Infections; interferon-gamma; Interferon-gamma - secretion; Macaca; Monkeys & apes; Mortality; neutralization; neutralizing antibodies; Phospholipids - administration & dosage; Proteins; Recombinant; Saponins - administration & dosage; Studies; Subunit; subunit vaccines; T-lymphocytes; T-Lymphocytes - immunology; Vaccines; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - genetics; Vaccines, Subunit - immunology; Vaccines, Subunit - isolation & purification; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; Vaccines, Synthetic - isolation & purification; Vector-borne diseases; viral load; Viruses; ISE, USA, Hawaii; Hawaii; Subunit; Dengue vaccine; Recombinant

•DEN-80E formulated with ISCOMATRIX™ adjuvant is immunogenic in non-human primates.•A 0, 1, 6 month schedule results in higher antibody titers compared to 0, 1, 2 months.•The monovalent DEN1-80E vaccine was safe and immunogenic in human subjects. This review focuses on a dengue virus (DENV) vaccine...